港股異動丨雍禾醫療漲超10.6% 2024年業績表現穩健+中金維持“跑贏行業”評級
雍禾醫療(2279.HK)漲超10.6%,報1.25港元。消息面上,雍禾醫療公佈,截至2024年12月31日止年度,集團的收入增加1.5%至18.045億元,毛利增加8.7%至10.842億元,毛利率由上年度的56.1%增加至60.1%。截至2024年12月31日,公司在全國63個城市擁有66家植髮醫療機構,在上海、廣州、深圳擁有8家史雲遜健發機構,爲中國最大及覆蓋城市最廣的連鎖毛髮醫療集團。報告期內,公司服務患者總人數逾12萬人。
中金髮布研報指,雍禾醫療全年業績基本符合市場預期,核心業務收入保持平穩,平均消費穩中有升,門店佈局優化+精細化營銷助力運營效率與盈利能力提升,維持對其“跑贏行業”評級。展望2025年,公司計劃進一步深化內部管理改革,通過精細化運營提升效率,持續推動降本增效。(格隆匯)
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.